The beneficial effects of tamoxifen on arteries: A key player for cardiovascular health of breast cancer patient
Biochemical Pharmacology · 2023
DOI: 10.1016/j.bcp.2023.115677 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Morgane Davezac und 7 weiteren Autor:innen. Beteiligte Einrichtung: I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM) U1297, University of Toulouse 3, Toulouse, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Cardiovascular Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 134 Literaturangaben. Gefördert von: Ligue Contre le Cancer, Fondation de France, Institut National de la Santé et de la Recherche Médicale.
Abstract (Originalsprache)
Breast cancer is the most common cancer in women. Over the past few decades, advances in cancer detection and treatment have significantly improved survival rate of breast cancer patients. However, due to the cardiovascular toxicity of cancer treatments (chemotherapy, anti-HER2 antibodies and radiotherapy), cardiovascular diseases (CVD) have become an increasingly important cause of long-term morbidity and mortality in breast cancer survivors. Endocrine therapies are prescribed to reduce the risk of recurrence and specific death in estrogen receptor-positive (ER +) early breast cancer patients, but their impact on CVD is a matter of debate. Whereas aromatase inhibitors and luteinizing hormone-releasing hormone (LHRH) analogs inhibit estrogen synthesis, tamoxifen acts as a selective estrogen receptor modulator (SERM), opposing estrogen action in the breast but mimicking their actions in other tissues, including arteries. This review aims to summarize the main clinical and experimental studies reporting the effects of tamoxifen on CVD. In addition, we will discuss how recent findings on the mechanisms of action of these therapies may contribute to a better understanding and anticipation of CVD risk in breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM) U1297, University of Toulouse 3, Toulouse, France.
- I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM) U1297, University of Toulouse 3, Toulouse, France; PhysioStim, 10 rue Henri Regnault, 81100, Castres, France.
- I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM) U1297, University of Toulouse 3, Toulouse, France; CREFRE-Anexplo, Service de Microchirurgie Experimentale, UMS006, INSERM, Université de Toulouse…
- Department of Medical Oncology, Claudius Regaud Institute, IUCT-Oncopole, Toulouse, France.
- I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM) U1297, University of Toulouse 3, Toulouse, France. Electronic address: coralie.fontaine@inserm.fr.
Förderung
- Ligue Contre le Cancer
- Fondation de France
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Université de Toulouse
Zitieren
APA
Davezac, M., Meneur, C., Buscato, M., Zahreddine, R., Arnal, J. F., Dalenc, F., Lenfant, F., & Fontaine, C. (2023). The beneficial effects of tamoxifen on arteries: A key player for cardiovascular health of breast cancer patient. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115677
Vancouver
Davezac M, Meneur C, Buscato M, Zahreddine R, Arnal JF, Dalenc F, et al. The beneficial effects of tamoxifen on arteries: A key player for cardiovascular health of breast cancer patient. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115677
BibTeX
@article{Davezac2023,
author = {Davezac, Morgane and Meneur, Cecile and Buscato, Melissa and Zahreddine, Rana and Arnal, Jean-François and Dalenc, Florence and Lenfant, Françoise and Fontaine, Coralie},
title = {The beneficial effects of tamoxifen on arteries: A key player for cardiovascular health of breast cancer patient},
journal = {Biochemical Pharmacology},
year = {2023},
doi = {10.1016/j.bcp.2023.115677}
}
EUVIMED